$AFIB
Acutus Medical, Inc. Stock $afib

$afib Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000162828022029539 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$4.962M	$3.644M
YoY Change	13.76%	-20.8%
Cost Of Revenue	$8.321M	$6.951M
YoY Change	-16.28%	-18.6%
Gross Profit	-$3.359M	-$3.307M
YoY Change	-39.77%	-16.02%
Gross Profit Margin	-67.69%	-90.75%
Selling, General & Admin	$9.447M	$9.679M
YoY Change	-40.45%	-38.76%
% of Gross Profit
Research & Development	$6.269M	$5.946M
YoY Change	-29.08%	-36.06%
% of Gross Profit
Depreciation & Amortization	$1.457M	$1.500M
YoY Change	-13.63%	0.0%
% of Gross Profit
Operating Expenses	$15.62M	$15.63M
YoY Change	-35.8%	-37.76%
Operating Profit	-$18.98M	-$20.46M
YoY Change	-36.54%	-24.47%
Interest Expense	-$763.0K	$1.109M
YoY Change	-44.06%	-23.04%
% of Operating Profit
Other Income/Expense, Net	-$871.0K	$36.00K
YoY Change		-102.53%
Pretax Income	$15.19M	-$20.43M
YoY Change	-148.59%	-28.36%
Income Tax	$82.00K	$0.00
% Of Pretax Income	0.54%
Net Earnings	$15.11M	-$20.43M
YoY Change	-148.32%	-28.36%
Net Earnings / Revenue	304.47%	-560.51%
Basic Earnings Per Share		-$0.72
Diluted Earnings Per Share	$0.41	-$0.72
COMMON SHARES
Basic Shares Outstanding	28.45M shares	28.37M shares
Diluted Shares Outstanding		28.36M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$70.45M	$66.30M
YoY Change	-30.09%	-49.18%
Cash & Equivalents	$25.58M	$28.00M
Short-Term Investments	$44.86M	$38.30M
Other Short-Term Assets	$13.01M	$9.783M
YoY Change	137.55%	57.92%
Inventory	$13.33M	$14.60M
Prepaid Expenses
Receivables	$21.09M	$3.213M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$117.9M	$93.89M
YoY Change	-6.67%	-39.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$13.09M	$10.09M
YoY Change	-4.22%	-30.89%
Goodwill	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Intangibles	$1.583M	$1.633M
YoY Change	-68.42%	-68.43%
Long-Term Investments	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Other Assets	$897.0K	$986.0K
YoY Change	-22.14%	-9.21%
Total Long-Term Assets	$15.57M	$20.73M
YoY Change	-64.2%	-50.19%
TOTAL ASSETS
Total Short-Term Assets	$117.9M	$93.89M
Total Long-Term Assets	$15.57M	$20.73M
Total Assets	$133.4M	$114.6M
YoY Change	-21.41%	-41.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.721M	$4.638M
YoY Change	-37.21%	-27.72%
Accrued Expenses	$10.01M	$8.917M
YoY Change	9.99%	-5.12%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.800M	$1.900M
YoY Change	20.0%	0.0%
Total Short-Term Liabilities	$19.87M	$18.32M
YoY Change	7.36%	0.78%
LONG-TERM LIABILITIES
Long-Term Debt	$34.43M	$34.31M
YoY Change	-14.8%	-14.32%
Other Long-Term Liabilities	$4.115M	$10.00K
YoY Change	8130.0%	-44.44%
Total Long-Term Liabilities	$38.55M	$34.32M
YoY Change	-4.73%	-14.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.87M	$18.32M
Total Long-Term Liabilities	$38.55M	$34.32M
Total Liabilities	$58.42M	$56.85M
YoY Change	-8.81%	-10.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$518.3M	-$533.4M
YoY Change	8.27%	19.22%
Common Stock	$29.00K	$28.00K
YoY Change	3.57%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$75.02M	$57.78M
YoY Change
Total Liabilities & Shareholders Equity	$133.4M	$114.6M
YoY Change	-21.41%	-41.94%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	$15.11M	-$20.43M
YoY Change	-148.32%	-28.36%
Depreciation, Depletion And Amortization	$1.457M	$1.500M
YoY Change	-13.63%	0.0%
Cash From Operating Activities	-$12.98M	-$23.83M
YoY Change	-42.52%	-12.33%
INVESTING ACTIVITIES
Capital Expenditures	$1.510M	-$755.0K
YoY Change	-144.6%	1.21%
Acquisitions
YoY Change
Other Investing Activities	$13.73M	$6.608M
YoY Change	-270.78%	-337.19%
Cash From Investing Activities	$12.22M	$5.853M
YoY Change	-206.94%	-265.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-15.00K	-458.0K
YoY Change	-97.08%	-100.56%
NET CHANGE
Cash From Operating Activities	-12.98M	-23.83M
Cash From Investing Activities	12.22M	5.853M
Cash From Financing Activities	-15.00K	-458.0K
Net Change In Cash	-777.0K	-18.44M
YoY Change	-97.75%	-135.8%
FREE CASH FLOW
Cash From Operating Activities	-$12.98M	-$23.83M
Capital Expenditures	$1.510M	-$755.0K
Free Cash Flow	-$14.49M	-$23.08M
YoY Change	-24.52%	-12.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001522860
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39430
	dei	Entity Registrant Name EntityRegistrantName	ACUTUS MEDICAL, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-1306615
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2210 Faraday Ave.
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Carlsbad
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92008
	dei	City Area Code CityAreaCode	442
	dei	Local Phone Number LocalPhoneNumber	232-6080
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	AFIB
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28452247	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28003000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24071000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	38299000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	76702000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	150000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	150000	usd
CY2022Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3213000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3633000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	14596000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	16408000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9633000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5326000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	93894000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	126290000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	7120000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4000000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10087000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13670000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4027000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4521000	usd
CY2022Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1633000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5013000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	0	usd
CY2021Q4	us-gaap	Goodwill Goodwill	12026000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	986000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1152000	usd
CY2022Q3	us-gaap	Assets Assets	114627000	usd
CY2021Q4	us-gaap	Assets Assets	169792000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4638000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7519000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8917000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9096000	usd
CY2022Q3	afib	Shortterm Contingent Consideration ShorttermContingentConsideration	1900000	usd
CY2021Q4	afib	Shortterm Contingent Consideration ShorttermContingentConsideration	1500000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	392000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	395000	usd
CY2022Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2475000	usd
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	18322000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	18510000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4204000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4591000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34310000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	40415000	usd
CY2022Q3	afib	Longterm Contingent Consideration LongtermContingentConsideration	0	usd
CY2021Q4	afib	Longterm Contingent Consideration LongtermContingentConsideration	500000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	10000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	50000	usd
CY2022Q3	us-gaap	Liabilities Liabilities	56846000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	64066000	usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	6666	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	6666	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	6666	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	6666	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	260000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	260000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28373788	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28373788	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27957223	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27957223	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	28000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	28000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	592296000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	584613000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-533422000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1121000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-478698000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-217000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57781000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	105726000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	114627000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	169792000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3644000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4601000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11401000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12901000	usd
CY2022Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6951000	usd
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8539000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	23589000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	22986000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5946000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9299000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21884000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27843000	usd
CY2022Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9679000	usd
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15805000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38207000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	47658000	usd
CY2022Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2021Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	12026000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2022Q3	us-gaap	Restructuring Charges RestructuringCharges	1331000	usd
CY2021Q3	us-gaap	Restructuring Charges RestructuringCharges	0	usd
	us-gaap	Restructuring Charges RestructuringCharges	2280000	usd
	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2022Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	198000	usd
CY2021Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-1953000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	1153000	usd
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-3364000	usd
CY2022Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2021Q3	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	43575000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	24105000	usd
CY2021Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	31690000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	55564000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	95123000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20461000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-27089000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44163000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-82222000	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2021Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7947000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-904000	usd
CY2021Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-904000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2022Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	241000	usd
CY2021Q3	us-gaap	Interest And Other Income InterestAndOtherIncome	19000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	292000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	88000	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	1109000	usd
CY2021Q3	us-gaap	Interest Expense InterestExpense	1441000	usd
	us-gaap	Interest Expense InterestExpense	3810000	usd
	us-gaap	Interest Expense InterestExpense	4285000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	36000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1422000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10561000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4197000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20425000	usd
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28511000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54724000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-86419000	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20425000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-28511000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54724000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-86419000	usd
CY2022Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	39000	usd
CY2021Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-13000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-351000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-183000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-904000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-317000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20737000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28707000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55628000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-86739000	usd
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.72
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.72
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.94
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.93
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.93
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.99
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.99
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28359516	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28359516	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30460466	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	30460466	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28273207	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28273207	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28890382	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28890382	shares
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	76651000	usd
CY2022Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	39000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-351000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	1867000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-20425000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-183000	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57781000	usd
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	75856000	usd
CY2021Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-13000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	5885	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	82664000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	84000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	3350000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	440000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-28511000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	133687000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	105726000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-904000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	66000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	7435000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	182000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54724000	usd
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	5885	usd
CY2022Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57781000	usd
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	126583000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-317000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	82664000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	703000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	10036000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	440000	usd
	afib	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	0	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-86419000	usd
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	133687000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54724000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-86419000	usd
	us-gaap	Depreciation Depreciation	4653000	usd
	us-gaap	Depreciation Depreciation	4227000	usd
	afib	Change In Property Plant And Equipment Converted To Sales ChangeInPropertyPlantAndEquipmentConvertedToSales	-266000	usd
	afib	Change In Property Plant And Equipment Converted To Sales ChangeInPropertyPlantAndEquipmentConvertedToSales	0	usd
	us-gaap	Sales Type Lease Selling Profit Loss SalesTypeLeaseSellingProfitLoss	87000	usd
	us-gaap	Sales Type Lease Selling Profit Loss SalesTypeLeaseSellingProfitLoss	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	370000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	480000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	7497000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	10263000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-237000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1011000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	741000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1032000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	480000	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	496000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	12026000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7947000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	43575000	usd
	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
	afib	Payments For Direct Costs In Divestiture Of Business PaymentsForDirectCostsInDivestitureOfBusiness	2917000	usd
	afib	Payments For Direct Costs In Divestiture Of Business PaymentsForDirectCostsInDivestitureOfBusiness	0	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-904000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
	afib	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	1153000	usd
	afib	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	-3364000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-420000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2030000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1812000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2004000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4296000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	59000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-386000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	369000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2929000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1813000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-179000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1862000	usd
	afib	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-390000	usd
	afib	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-432000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-40000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	18000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-72053000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77101000	usd
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	50000000	usd
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	33235000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	70020000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	18599000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	8590000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	59642000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	98507000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2473000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6587000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	92533000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	30490000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	44550000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1063000	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	34825000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	626000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	572000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	873000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	3152000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	82664000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	62000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	703000	usd
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	182000	usd
	us-gaap	Proceeds From Repayment Of Loans By Employee Stock Ownership Plans ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans	440000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-12101000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80083000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-447000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-214000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	7932000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	33258000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24221000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32153000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25384000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58642000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	38000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3101000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3109000	usd
	afib	Proceeds From Issuance Of Long Term Debt Allocated To Warrant Liability ProceedsFromIssuanceOfLongTermDebtAllocatedToWarrantLiability	3379000	usd
	afib	Proceeds From Issuance Of Long Term Debt Allocated To Warrant Liability ProceedsFromIssuanceOfLongTermDebtAllocatedToWarrantLiability	0	usd
	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	0	usd
	us-gaap	Debt Securities Unrealized Gain Loss DebtSecuritiesUnrealizedGainLoss	-3000	usd
	afib	Unpaid Purchases Of Property Plant And Equipment UnpaidPurchasesOfPropertyPlantAndEquipment	48000	usd
	afib	Unpaid Purchases Of Property Plant And Equipment UnpaidPurchasesOfPropertyPlantAndEquipment	36000	usd
	afib	Financing Costs Incurred But Not Yet Paid FinancingCostsIncurredButNotYetPaid	380000	usd
	afib	Financing Costs Incurred But Not Yet Paid FinancingCostsIncurredButNotYetPaid	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3527000	usd
	afib	Net Book Value Of Equipment Sales Type Lease NetBookValueOfEquipmentSalesTypeLease	244000	usd
	afib	Net Book Value Of Equipment Sales Type Lease NetBookValueOfEquipmentSalesTypeLease	0	usd
CY2022Q3	afib	Cash Cash Equivalents Restricted Cash And Short Term Investments CashCashEquivalentsRestrictedCashAndShortTermInvestments	70500000	usd
CY2021Q4	afib	Cash Cash Equivalents Restricted Cash And Short Term Investments CashCashEquivalentsRestrictedCashAndShortTermInvestments	108000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-54700000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-86400000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-72100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77100000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-533400000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-478700000	usd
CY2022Q3	afib	Working Capital WorkingCapital	75600000	usd
CY2021Q4	afib	Working Capital WorkingCapital	107800000	usd
CY2020Q3	afib	Proceeds From Sale Of Convertible Preferred Stock And Convertible Debt ProceedsFromSaleOfConvertiblePreferredStockAndConvertibleDebt	253900000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates and Assumptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and disclosures of contingent assets and liabilities. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ from those estimates.</span></div>
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4000000	usd
	afib	Restricted Cash Indemnity Escrow Account Holding Period RestrictedCashIndemnityEscrowAccountHoldingPeriod	P18M
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28003000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24071000	usd
CY2022Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	150000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	150000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4000000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32153000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	24221000	usd
CY2021Q3	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	usd
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	usd
CY2022Q3	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	usd
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist principally of cash, cash equivalents, restricted cash, accounts receivable and marketable securities. Cash and restricted cash are maintained in accounts with financial institutions which, at times, may exceed the federal depository insurance coverage of $0.25 million. The Company has not experienced losses on these accounts, and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. The Company’s marketable securities portfolio primarily consists of investments in commercial paper, Yankee debt securities, supranational, U.S. treasury securities, asset-backed securities and short-term high credit quality corporate debt securities.</span></div>
CY2022Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3644000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4601000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11401000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12901000	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	3644000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4601000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11401000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	12901000	usd
CY2022Q3	us-gaap	Inventory Write Down InventoryWriteDown	200000	usd
CY2021Q3	us-gaap	Inventory Write Down InventoryWriteDown	100000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	2600000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	1000000	usd
CY2022Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reportingunit
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	12000000	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2021Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	65005000	usd
CY2022Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	4375000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	105715000	usd
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2000000	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4000000	usd
	afib	Restricted Cash Indemnity Escrow Account Holding Period RestrictedCashIndemnityEscrowAccountHoldingPeriod	P18M
CY2022Q3	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	38346000	usd
CY2022Q3	afib	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax	0	usd
CY2022Q3	afib	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax	47000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	38299000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	38346000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	47000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	38299000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	76741000	usd
CY2021Q4	afib	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Current Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrentBeforeTax	0	usd
CY2021Q4	afib	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Current Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrentBeforeTax	39000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	76702000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	7126000	usd
CY2021Q4	afib	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Noncurrent Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainNoncurrentBeforeTax	0	usd
CY2021Q4	afib	Debt Securities Available For Sale Accumulated Gross Unrealized Loss Noncurrent Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossNoncurrentBeforeTax	6000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	7120000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	83867000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	45000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	83822000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	38300000	usd
CY2022Q3	afib	Debt Securities Available For Sale Current Term DebtSecuritiesAvailableForSaleCurrentTerm	P1Y
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	76700000	usd
CY2021Q4	afib	Debt Securities Available For Sale Current Term DebtSecuritiesAvailableForSaleCurrentTerm	P1Y
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	7100000	usd
CY2021Q4	afib	Debt Securities Available For Sale Noncurrent Term DebtSecuritiesAvailableForSaleNoncurrentTerm	P2Y
CY2022Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	9355000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6779000	usd
CY2022Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2021000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1772000	usd
CY2022Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3220000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7857000	usd
CY2022Q3	us-gaap	Inventory Net InventoryNet	14596000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	16408000	usd
CY2022Q3	us-gaap	Sales Type Lease Lease Income SalesTypeLeaseLeaseIncome	200000	usd
CY2021Q3	us-gaap	Sales Type Lease Lease Income SalesTypeLeaseLeaseIncome	200000	usd
	us-gaap	Sales Type Lease Lease Income SalesTypeLeaseLeaseIncome	300000	usd
	us-gaap	Sales Type Lease Lease Income SalesTypeLeaseLeaseIncome	700000	usd
CY2022Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Remainder Of Fiscal Year SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear	139000	usd
CY2022Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths	490000	usd
CY2022Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears	537000	usd
CY2022Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears	174000	usd
CY2022Q3	us-gaap	Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived	1340000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	24832000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25572000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14745000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13670000	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Property Plant And Equipment DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment	500000	usd
CY2022Q3	us-gaap	Depreciation Depreciation	1500000	usd
CY2021Q3	us-gaap	Depreciation Depreciation	1500000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	11902000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10087000	usd
	us-gaap	Depreciation Depreciation	4700000	usd
	us-gaap	Depreciation Depreciation	4200000	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2021Q3	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2021Q4	us-gaap	Goodwill Goodwill	12026000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5013000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	370000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	12026000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-3010000	usd
CY2022Q3	us-gaap	Goodwill Goodwill	0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1633000	usd
CY2022Q3	us-gaap	Disposal Group Including Discontinued Operation Intangible Assets DisposalGroupIncludingDiscontinuedOperationIntangibleAssets	3000000	usd
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	12000000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2000000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	367000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1633000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6300000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1287000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5013000	usd
CY2022Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000	usd
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2021Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	50000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	200000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	200000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	200000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	200000	usd
CY2022Q3	afib	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	783000	usd
CY2022Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1633000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6539000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7088000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	194000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	158000	usd
CY2022Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	571000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	401000	usd
CY2022Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	427000	usd
CY2021Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	71000	usd
CY2022Q3	afib	Clinical Studies Current ClinicalStudiesCurrent	304000	usd
CY2021Q4	afib	Clinical Studies Current ClinicalStudiesCurrent	541000	usd
CY2022Q3	afib	Clinical Accounts Current ClinicalAccountsCurrent	338000	usd
CY2021Q4	afib	Clinical Accounts Current ClinicalAccountsCurrent	358000	usd
CY2022Q3	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	105000	usd
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	129000	usd
CY2022Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	85000	usd
CY2021Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	354000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	350000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8917000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9096000	usd
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	36750000	usd
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	44550000	usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7900000	usd
CY2022Q3	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	2440000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	4135000	usd
CY2022Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	34310000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	40415000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	631000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	617000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M24D
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M18D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2022Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	252000	usd
CY2021Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	247000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	768000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	701000	usd
CY2022Q3	us-gaap	Variable Lease Cost VariableLeaseCost	77000	usd
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	83000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	216000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	243000	usd
CY2022Q3	us-gaap	Lease Cost LeaseCost	329000	usd
CY2021Q3	us-gaap	Lease Cost LeaseCost	330000	usd
	us-gaap	Lease Cost LeaseCost	984000	usd
	us-gaap	Lease Cost LeaseCost	944000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	365000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1130000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1162000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1151000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1185000	usd
CY2022Q3	afib	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	1221000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6214000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1618000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	4596000	usd
CY2022Q3	afib	Number Of Class Action Lawsuits NumberOfClassActionLawsuits	2	lawsuit
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4576505	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	797487	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	797487	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.41
CY2021Q4	afib	Class Of Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P6Y10M24D
	afib	Class Of Warrant Or Right Granted In Period ClassOfWarrantOrRightGrantedInPeriod	3779018	shares
	afib	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted In Period ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod	1.11
	afib	Class Of Warrant Or Right Weighted Average Remaining Contractual Life Granted In Period ClassOfWarrantOrRightWeightedAverageRemainingContractualLifeGrantedInPeriod	P7Y9M18D
CY2022Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4576505	shares
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.56
CY2022Q3	afib	Class Of Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P7Y6M
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-900000	usd
CY2020Q3	afib	Common And Preferred Stock Warrant Liability CommonAndPreferredStockWarrantLiability	14500000	usd
	afib	Number Of Warrant Holders NumberOfWarrantHolders	4	holder
	afib	Conversion Of Stock Maximum Number Of Shares Held After Conversion Percentage Of Common Stock Outstanding ConversionOfStockMaximumNumberOfSharesHeldAfterConversionPercentageOfCommonStockOutstanding	0.049
	afib	Conversion Of Stock Maximum Number Of Shares Held After Conversion Percentage Of Common Stock Outstanding After Written Notice Election ConversionOfStockMaximumNumberOfSharesHeldAfterConversionPercentageOfCommonStockOutstandingAfterWrittenNoticeElection	0.099
CY2021Q3	afib	Number Of Investors NumberOfInvestors	4	investor
	afib	Conversion Of Stock Maximum Number Of Shares Held After Conversion Percentage Of Common Stock Outstanding ConversionOfStockMaximumNumberOfSharesHeldAfterConversionPercentageOfCommonStockOutstanding	0.049
	afib	Common Stock Conversion Written Notice Election Period CommonStockConversionWrittenNoticeElectionPeriod	P61D
	afib	Conversion Of Stock Maximum Number Of Shares Held After Conversion Percentage Of Common Stock Outstanding After Written Notice Election ConversionOfStockMaximumNumberOfSharesHeldAfterConversionPercentageOfCommonStockOutstandingAfterWrittenNoticeElection	0.099
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6325000	shares
CY2021Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	82700000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	700000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0176
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0339
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0076
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0139
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.75
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.90
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.60
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.75
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3781636	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.12
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	93000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	776550	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.48
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	35478	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.85
	afib	Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueExercised	33000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1254926	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	10.24
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3267782	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.68
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	44000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1987396	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.72
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
	afib	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Grant Date Fair Value Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageGrantDateFairValueExercisePrice	0.88
CY2021	afib	Sharebased Compensation Arrangement By Sharebased Payment Award Options Weighted Average Grant Date Fair Value Exercise Price SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsWeightedAverageGrantDateFairValueExercisePrice	3.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.66
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	7900000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1884000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3577000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7497000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10263000	usd
CY2022Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1.34
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16271309	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12286925	shares

Files In Submission

Name	View Source	Status
0001628280-22-029539-index-headers.html	Edgar Link	pending
0001628280-22-029539-index.html	Edgar Link	pending
0001628280-22-029539.txt	Edgar Link	pending
0001628280-22-029539-xbrl.zip	Edgar Link	pending
afib-20220930.htm	Edgar Link	pending
afib-20220930.xsd	Edgar Link	pending
afib-20220930x10qex311.htm	Edgar Link	pending
afib-20220930x10qex312.htm	Edgar Link	pending
afib-20220930x10qex321.htm	Edgar Link	pending
afib-20220930x10qex322.htm	Edgar Link	pending
afib-20220930_g1.jpg	Edgar Link	pending
afib2022093010qex102.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
afib-20220930_def.xml	Edgar Link	unprocessable
afib-20220930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
afib-20220930_htm.xml	Edgar Link	completed
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
afib-20220930_cal.xml	Edgar Link	unprocessable
afib-20220930_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AFIB
Acutus Medical, Inc. Stock $afib

2022 Q4 Form 10-Q Financial Statement

#000162828022029539 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AFIB Acutus Medical, Inc. Stock $afib

2022 Q4 Form 10-Q Financial Statement

#000162828022029539 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AFIB
Acutus Medical, Inc. Stock $afib